Skip to main content

Marc N. Aspis

Associate

[email protected]

+1.212.692.6772

Share:

Marc handles transaction-related tax matters pertaining to employment benefits and compensation

and also provides compliance counseling related to employment retirement plans, ERISA, and PBGC regulations. He regularly conducts tax and employee benefits/executive compensation due diligence for mergers and acquisitions and other commercial transactions.

Prior to joining Mintz, Marc was an associate in the tax and personal planning, employee benefits, and employment practices of a mid-size New York law firm. He represented clients in tax matters related to mergers, acquisitions, cross-border transactions, international M&A transactions, real estate investments, and joint ventures. In addition, Marc counseled foreign clients on tax planning and provided advice on a broad range of additional tax issues. His experience included defending a client in an $800,000 state tax audit. 

Earlier Marc worked at PricewaterhouseCoopers (PwC). As a senior tax associate in the international tax services division, he helped clients structure transactions in a tax-efficient manner, focusing on the US federal income tax implications of cross-border and international transactions, including M&As.

While earning his LLM in taxation, Marc served as a judicial extern for the United States Tax Court. After completing law school, he was an associate in a New York law firm’s commercial litigation practice.

Marc also served as an infantry sergeant in the Israel Defense Forces.

Education

  • Georgetown University Law Center (LLM)
  • Boston University School of Law (JD)
  • Columbia University (BA)

Languages

- Hebrew

- Spanish

Recent Insights

News & Press

News & Press

Press Release Thumbnail
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.